Piramal Pharma Limited says it has completed the acquisition of a controlling stake in Yapan Bio Private Limited. The transaction follows Piramal’s earlier involvement with the company and extends its role in Yapan Bio’s operations.
Yapan Bio is described as providing process development, characterization, and phase I and II GMP manufacturing services for vaccines and biologics. Piramal states that it has held a stake in Yapan Bio since 2021, which it says has helped support the expansion of capabilities across biologics.
Across the outlets provided, the coverage is consistent on the completion of the controlling-stake acquisition and on Yapan Bio’s business focus. The sources largely present the deal as a step to strengthen service offerings related to early-stage clinical and GMP manufacturing for vaccine and biologics programs. No material differences in deal terms, timelines, or financial details are included in the excerpts shared.
